3D-Printed Polypills in Precision Medicine: Transforming Multidrug Therapy For Metabolic Syndrome

Abstract

Advanced 3D printing technology enables the production of customized polypills where multiple drugs are arranged in distinct regions and finely tuned control over each drug's dose release kinetics, and geometry by using technologies such as extrusion, stereolithography (SLA), and multi-material inkjet printing. It includes designing specific drug-polymer matrices, layered architectures, with controlled drug kinetics via infilled patterns, shell thickness, and Hot-Melt Extrusion filament, supporting flexible and patient-specific multi-drug therapy. In current research, Emerging Metabolic Syndrome polypill formulations together with statins, antihypertensives, antidiabetic drugs include GLP-1 receptor agonists and DPP-4 inhibitors, low-dose aspirin, and anti-obesity agents, with careful tuning of compatibility and release profiles using layered 3D printing, polymer matrices, and pH-responsive coatings. Precision-driven 3D printed Metabolic Syndrome polypills leverage pharmacogenomics, digital health data, and point-of-care production systems to tailor treatment for each patient. To ensure optimal and personalized drug exposure, metabolic syndrome polypills are evaluated using content uniformity, physicochemical and dissolution studies, release kinetics modeling, preclinical pharmacokinetics, and IVIVC-guided or virtual bioequivalence assessments. At Present, 3D printed polypills are governed by conventional drug device and GMP regulations, supported by the US FDA, EMA, and ICH (Q8-Q12). From experimental to clinical use, 3D-printed polypill production depends on multi-printer networks, QbD-based process control, PAT-enabled real-time monitoring, efficient material management, and cost-effective approaches for customized, low-volume manufacturing. Futuristic development in 3D printed polypills will focus on AI-driven formulations and geometries, 4D-responsive tablet system manufacturing models, cutting-edge organ-on-chip and PBPK models, and convergence with digital therapeutics and precision nutrition platforms to achieve truly personalized cardiometabolic therapy.